The Glomerulus: Mechanisms of Injury

[1]  R. Bellomo,et al.  Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2012, Critical Care.

[2]  H. Kawachi,et al.  Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. , 2008, Kidney international.

[3]  R. Bellomo,et al.  Pathophysiology of septic acute kidney injury: What do we really know? , 2008, Critical care medicine.

[4]  John A. Kellum,et al.  Acute kidney injury , 2008, Critical care medicine.

[5]  S. Bagshaw,et al.  Conventional markers of kidney function , 2008, Critical care medicine.

[6]  V. Ranieri,et al.  Circulating plasma factors induce tubular and glomerular alterations in septic burns patients , 2008, Critical care.

[7]  W. Comper,et al.  Resolved: normal glomeruli filter nephrotic levels of albumin. , 2008, Journal of the American Society of Nephrology : JASN.

[8]  R. Hébert,et al.  Prostaglandins in the kidney: developments since Y2K. , 2007, Clinical science.

[9]  J. Floege,et al.  Renal side effects of anti-VEGF therapy in man: a new test system. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  J. López-Novoa,et al.  Glomerular nephrotoxicity of aminoglycosides. , 2007, Toxicology and applied pharmacology.

[11]  S. Karumanchi,et al.  The glomerular injury of preeclampsia. , 2007, Journal of the American Society of Nephrology : JASN.

[12]  M. Camici.  Urinary detection of podocyte injury. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  F. Peale,et al.  Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies , 2007, Proceedings of the National Academy of Sciences.

[14]  P. Coates,et al.  Nephrotoxicity and calcineurin inhibitors , 2007 .

[15]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  R. Toto,et al.  Nephrotic syndrome after bevacizumab: case report and literature review. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  M. Manji,et al.  Microalbuminuria in the intensive care unit: Clinical correlates and association with outcomes in 431 patients* , 2006, Critical care medicine.

[18]  G. Habib,et al.  Penicillamine and nephrotic syndrome. , 2006, European journal of internal medicine.

[19]  S. Shankland,et al.  The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.

[20]  M. Kleinberg.  What is the current and future status of conventional amphotericin B? , 2006, International journal of antimicrobial agents.

[21]  R. Harris,et al.  COX-2 and the Kidney , 2006, Journal of cardiovascular pharmacology.

[22]  R. Bellomo,et al.  Renal blood flow in experimental septic acute renal failure. , 2006, Kidney international.

[23]  J. López-Novoa,et al.  Resveratrol inhibits gentamicin-induced mesangial cell contraction. , 2006, Life sciences.

[24]  H. Aukema,et al.  Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys. , 2006, American journal of physiology. Renal physiology.

[25]  T. Aso,et al.  Estrogen Replacement Effectively Improves the Accelerated Intimal Hyperplasia Following Balloon Injury of Carotid Artery in the Ovariectomized Rats , 2006, Journal of cardiovascular pharmacology.

[26]  H. Trachtman,et al.  Urinary Podocyte mRNA Excretion in Children with D+HUS: A Potential Marker of Long-Term Outcome , 2006, Renal failure.

[27]  G. Gamba,et al.  Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. , 2005, American journal of physiology. Renal physiology.

[28]  V. Launay-Vacher,et al.  Néphrotoxicité des médicaments : veille bibliographique janvier 2003–décembre 2004 , 2005 .

[29]  A. Christensson,et al.  Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. , 2005, Clinical chemistry.

[30]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[31]  E. Martino,et al.  Early effects of methylprednisolone infusion on serum cystatin C in patients with severe Graves' ophthalmopathy. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[32]  D. Brater,et al.  Renal Effects of the Cyclooxygenase‐inhibiting Nitric Oxide Donator AZD3582 Compared with Rofecoxib and Naproxen During Normal and Low Sodium Intake , 2005, Clinical pharmacology and therapeutics.

[33]  F. Bogazzi,et al.  Thyroid function differently affects serum cystatin Cand creatinine concentrations , 2005, Journal of endocrinological investigation.

[34]  J. Björk,et al.  A cystatin C‐based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft‐Gault formula , 2005, Scandinavian journal of clinical and laboratory investigation.

[35]  N. Landeiro,et al.  Change of extravascular lung water in sheep with early acute respiratory distress syndrome , 2005, Critical Care.

[36]  P. Villa,et al.  Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients , 2005, Critical care.

[37]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Bonventre,et al.  Biologic markers for the early detection of acute kidney injury , 2004, Current opinion in critical care.

[39]  A. Kribben,et al.  Early detection of acute renal failure by serum cystatin C. , 2004, Kidney international.

[40]  J. Chapman,et al.  Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology , 2004, Transplantation.

[41]  N. Žarković,et al.  Proatrial Natriuretic Peptide (1–98), but Not Cystatin C, Is Predictive for Occurrence of Acute Renal Insufficiency in Critically Ill Septic Patients , 2004, Nephron Clinical Practice.

[42]  Thomas Benzing,et al.  Signaling at the slit diaphragm. , 2004, Journal of the American Society of Nephrology : JASN.

[43]  F. Kabbinavar,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Spiegelman,et al.  Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. , 2004, Kidney international.

[45]  L. Tamer,et al.  N-Acetylcysteine inhibits peroxynitrite-mediated damage in oleic acid-induced lung injury , 2004, Pulmonary pharmacology & therapeutics.

[46]  A. Kribben,et al.  Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range , 2004, Annals of clinical biochemistry.

[47]  P. Adegboyega,et al.  Immunohistochemical Expression of Cyclooxygenase-2 in Normal Kidneys , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[48]  N. Munshi,et al.  Podocyte injury associated glomerulopathies induced by pamidronate. , 2004, Kidney international.

[49]  A. Tobar,et al.  Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[50]  F. Hoek,et al.  A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[52]  T. P. Cid,et al.  ANTIOXIDANT NUTRIENTS PROTECT AGAINST CYCLOSPORINE A NEPHROTOXICITY , 2003 .

[53]  M. Brändle,et al.  Impact of thyroid dysfunction on serum cystatin C. , 2003, Kidney international.

[54]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[55]  Y. Amoateng-Adjepong,et al.  Microalbuminuria in critically ill medical patients: Prevalence, predictors, and prognostic significance , 2003, Critical care medicine.

[56]  B. Keevil,et al.  Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. , 2003, Clinical chemistry.

[57]  A. Désormeaux,et al.  Blockade of the apoptotic machinery by cyclosporin A redirects cell death toward necrosis in arterial endothelial cells: regulation by reactive oxygen species and cathepsin D , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  S. Jagannath,et al.  Nephrotic proteinuria associated with high‐dose pamidronate in multiple myeloma , 2002, British journal of haematology.

[59]  J. Bolaños,et al.  Involvement of reactive oxygen species on gentamicin-induced mesangial cell activation. , 2002, Kidney international.

[60]  T. Slowinski,et al.  Interaction of the endothelin system and calcineurin inhibitors after kidney transplantation. , 2002, Clinical science.

[61]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[62]  M. Perazella,et al.  Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  P. Fine,et al.  Nephrotic syndrome after treatment with pamidronate. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[64]  R. Bing,et al.  Nitric Oxide, Anti-Inflammatory Drugs on Renal Prostaglandins and Cyclooxygenase-2 , 2002, Hypertension.

[65]  C. Clish,et al.  Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. , 2001, Biochemical and biophysical research communications.

[66]  T. Hishinuma,et al.  Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[67]  S. Pestotnik,et al.  The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. , 2001, The American journal of medicine.

[68]  S. Rosen,et al.  Difficulties in understanding human "acute tubular necrosis": limited data and flawed animal models. , 2001, Kidney international.

[69]  M. Farquhar,et al.  Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. , 2001, The Journal of clinical investigation.

[70]  R. Schrier,et al.  Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. , 2001, Kidney international.

[71]  P. Menè,et al.  Mesangial cell cultures. , 2001, Journal of nephrology.

[72]  D. Varonos,et al.  Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[73]  Tsutomu Inoue,et al.  FAT is a component of glomerular slit diaphragms. , 2001, Kidney international.

[74]  K. Sharma,et al.  Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. , 2001, Kidney international.

[75]  H. Gröne,et al.  Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. , 2000, Kidney international.

[76]  D. Varonos,et al.  Effect of nifedipine in cyclosporine-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[77]  D. Rodríguez‐Puyol,et al.  Imbalance in endothelial vasoactive factors as a possible cause of cyclosporin toxicity: a role for endothelin-converting enzyme. , 2000, The Journal of laboratory and clinical medicine.

[78]  G. Gamba,et al.  Nifedipine Prevents Changes in Nitric Oxide Synthase mRNA Levels Induced by Cyclosporine , 2000, Hypertension.

[79]  S. Abramson,et al.  Nitric Oxide Synthase/COX Cross-Talk: Nitric Oxide Activates COX-1 But Inhibits COX-2-Derived Prostaglandin Production1 , 2000, The Journal of Immunology.

[80]  Not Available Not Available,et al.  Literature Abstracts , 2001, Pediatric Nephrology.

[81]  C. Sprung,et al.  Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score , 2000, Intensive Care Medicine.

[82]  M. Masseroli,et al.  Role of Intrarenal Endothelin 1, Endothelin 3, and Angiotensin II Expression in Chronic Cyclosporin A Nephrotoxicity in Rats , 2000, Nephron Experimental Nephrology.

[83]  P. Tavares,et al.  Role of Calcium in Gentamicin-Induced Mesangial Cell Activation , 2000, Cellular Physiology and Biochemistry.

[84]  Corinne Antignac,et al.  NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome , 2000, Nature Genetics.

[85]  R. Harris,et al.  Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[86]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[87]  Michael Loran Dustin,et al.  Congenital nephrotic syndrome in mice lacking CD2-associated protein. , 1999, Science.

[88]  B. Connolly,et al.  Immunolocalization of cyclooxygenase‐2 in the macula densa of human elderly , 1999, FEBS letters.

[89]  K. Tryggvason,et al.  Nephrin is specifically located at the slit diaphragm of glomerular podocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[90]  V. Briner,et al.  Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. , 1999, Kidney international.

[91]  A. Whelton.  Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. , 1999, The American journal of medicine.

[92]  M. Daudon,et al.  Foscarnet-induced crystalline glomerulonephritis with nephrotic syndrome and acute renal failure after kidney transplantation. , 1999, Transplantation.

[93]  M. Wolzt,et al.  Renal hemodynamic effects of l-arginine and sodium nitroprusside in heart transplant recipients , 1999 .

[94]  I. Ichikawa,et al.  Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. , 1999, The Journal of clinical investigation.

[95]  F. Vincenti,et al.  Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine , 1998 .

[96]  A. Ristimäki,et al.  Inhibition by nitric oxide‐releasing compounds of prostacyclin production in human endothelial cells , 1998, British journal of pharmacology.

[97]  W. Kriz,et al.  Synaptopodin: An Actin-associated Protein in Telencephalic Dendrites and Renal Podocytes , 1997, The Journal of cell biology.

[98]  J. Pfeilschifter,et al.  Phospholipase A2 in mesangial cells: control mechanisms and functional importance. , 1997, Experimental nephrology.

[99]  A. Grubb,et al.  Renal handling of radiolabelled human cystatin C in the rat. , 1996, Scandinavian journal of clinical and laboratory investigation.

[100]  R. O. Day,et al.  Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. , 1996, Journal of human hypertension.

[101]  L. V. Van Gaal,et al.  Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[102]  I. Olafsson,et al.  Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. , 1995, Scandinavian journal of clinical and laboratory investigation.

[103]  W. Couser,et al.  Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. , 1995, Journal of the American Society of Nephrology : JASN.

[104]  V. Kon,et al.  Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. , 1995, Transplantation.

[105]  D. Webb,et al.  Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males , 1995, Journal of hypertension.

[106]  T. Lee,et al.  The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. , 1995, American journal of respiratory and critical care medicine.

[107]  R. González-Sarmiento,et al.  Gentamicin activates rat mesangial cells. A role for platelet activating factor. , 1995, Kidney international.

[108]  N. Bobadilla,et al.  Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. , 1994, Kidney international.

[109]  J. Bertram,et al.  Reactive oxygen species in puromycin aminonucleoside nephrosis: in vitro studies. , 1994, Kidney international.

[110]  G. Jennings,et al.  Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. , 1993, Circulation.

[111]  J. Conger,et al.  Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. , 1993, The Journal of clinical investigation.

[112]  M. Kester,et al.  Platelet‐activating factor stimulates multiple signaling pathways in cultured rat mesangial cells , 1992, Journal of cellular physiology.

[113]  T. Inagami,et al.  Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. , 1992, Kidney international.

[114]  R. Branch,et al.  Effect of amphotericin B on intracellular calcium levels in cultured glomerular mesangial cells. , 1992, European journal of pharmacology.

[115]  G. Ghiggeri,et al.  Puromycin aminonucleoside metabolism by glomeruli and glomerular epithelial cells in vitro. , 1991, Kidney international.

[116]  R. Wait,et al.  The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity. , 1991, Transplantation.

[117]  D. Brooks,et al.  Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. , 1991, European journal of pharmacology.

[118]  N. Markandu,et al.  Concentrations of N-terminal ProANP in human plasma: evidence for ProANP (1-98) as the circulating form. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[119]  C. Katlama,et al.  Foscarnet and crystals in glomerular capillary lumens , 1990, The Lancet.

[120]  G. Remuzzi,et al.  Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? , 1990, Kidney international.

[121]  N. Perico,et al.  Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. , 1990, Journal of the American Society of Nephrology : JASN.

[122]  J. Parrillo,et al.  Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. , 1990, Chest.

[123]  I. Olafsson,et al.  Structure and expression of the human cystatin C gene. , 1990, The Biochemical journal.

[124]  T. Inagami,et al.  Role of endothelin in cyclosporine-induced glomerular dysfunction. , 1990, Kidney international.

[125]  R. Branch,et al.  Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. , 1990, The Journal of pharmacology and experimental therapeutics.

[126]  J. Oudinet,et al.  Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. , 1989, Kidney international.

[127]  V. Ferrans,et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. , 1988, The New England journal of medicine.

[128]  A. Fogo,et al.  Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. , 1988, The Journal of clinical investigation.

[129]  L. Raij,et al.  Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanisms and influence of calcium channel blockade. , 1988, The Journal of pharmacology and experimental therapeutics.

[130]  E. Friedman,et al.  GRANULAR JUXTAGLOMERULAR CELL HYPERPLASIA CAUSED BY CYCLOSPORINE , 1987, Transplantation.

[131]  A. Evan,et al.  Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. , 1987, Transplantation.

[132]  W. Baricos,et al.  Renal neuraminidase. Characterization in normal rat kidney and measurement in experimentally induced nephrotic syndrome. , 1986, The Biochemical journal.

[133]  M. Karnovsky,et al.  Focal and segmental glomerulosclerosis following a single intravenous dose of puromycin aminonucleoside. , 1986, The American journal of pathology.

[134]  J. Bonventre,et al.  A role for oxygen free radicals in aminonucleoside nephrosis. , 1986, Kidney international.

[135]  B. Kasiske,et al.  Adriamycin-induced chronic proteinuria: a structural and functional study. , 1985, The Journal of laboratory and clinical medicine.

[136]  T. Ferris,et al.  Effect of cyclosporine administration on renal hemodynamics in conscious rats. , 1985, Kidney international.

[137]  J P Kriss,et al.  Limitations of creatinine as a filtration marker in glomerulopathic patients. , 1985, Kidney international.

[138]  G. Remuzzi,et al.  Low-protein diet prevents glomerular damage in adriamycin-treated rats. , 1985, Kidney international.

[139]  M. Karnovsky,et al.  Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro. , 1985, The American journal of pathology.

[140]  E. Lewis,et al.  Inhibition of glomerular visceral epithelial cell endocytosis during nephrosis induced by puromycin aminonucleoside. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[141]  J. Weening,et al.  Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[142]  N. Moreau,et al.  Effect of P and A site substrates on the binding of a macrolide to ribosomes. Analysis of the puromycin-induced stimulation. , 1984, European journal of biochemistry.

[143]  R. Branch,et al.  Amphotericin B nephrotoxicity in humans decreased by salt repletion. , 1983, The American journal of medicine.

[144]  H. Rennke,et al.  Glomerular permeability and polyanion in adriamycin nephrosis in the rat. , 1983, Kidney international.

[145]  R. Branch,et al.  Aminophylline inhibits renal vasoconstriction produced by intrarenal hypertonic saline. , 1983, The Journal of pharmacology and experimental therapeutics.

[146]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[147]  H. Rennke,et al.  Alterations in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[148]  D. Evans,et al.  Drugs and the kidney. , 1980, British journal of hospital medicine.

[149]  M. Molitch,et al.  Spurious serum creatinine elevations in ketoacidosis. , 1980, Annals of internal medicine.

[150]  R. Branch,et al.  The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. , 1980, The Journal of pharmacology and experimental therapeutics.

[151]  L. Navar,et al.  Tubuloglomerular feedback and single nephron function after converting enzyme inhibition in the rat. , 1979, The Journal of clinical investigation.

[152]  R. Painter.  Inhibition of DNA replicon initiation by 4-nitroquinoline 1-oxide, adriamycin, and ethyleneimine. , 1978, Cancer research.

[153]  N. Bachur,et al.  Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. , 1977, Molecular pharmacology.

[154]  Michael Af,et al.  Experimental model of focal sclerosis. II. Correlation with immunopathologic changes, macromolecular kinetics, and polyanion loss. , 1977 .

[155]  C. Lucas,et al.  Renal hemodynamic response to furosemide in septic and injured patients. , 1976, Surgery.

[156]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[157]  M. Karnovsky,et al.  An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. , 1975, Kidney international.

[158]  A. Michael,et al.  Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside. , 1975, The Journal of laboratory and clinical medicine.

[159]  A. Michael,et al.  Transfer of aminonucleoside nephrosis by renal transplantation. , 1972, The Journal of clinical investigation.

[160]  A. Michael,et al.  Experimental renal disease in monkeys. I. Aminonucleoside nephrosis. , 1962, Laboratory investigation; a journal of technical methods and pathology.

[161]  D. Hackel,et al.  Aminonucleoside nephrosis in rats. , 1958, Pediatrics.

[162]  Not Available Not Available.  Literature abstracts , 2001, Pediatric Nephrology.

[163]  M. Kretzler,et al.  The glomerular slit diaphragm is a modified adherens junction. , 2000, Journal of the American Society of Nephrology : JASN.

[164]  J. Bariéty,et al.  Effect of ketanserine in cyclosporine-induced renal dysfunction in rats. , 1995, Nephron.

[165]  J. Weening,et al.  Puromycin aminonucleoside and adriamycin disturb cytoskeletal and extracellular matrix protein organization, but not protein synthesis of cultured glomerular epithelial cells. , 1994, Experimental nephrology.

[166]  A. Janoff,et al.  Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities , 1993 .

[167]  T. Okigaki,et al.  Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. , 1992, Toxicology.

[168]  J. Briggs,et al.  The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[169]  L. Panton,et al.  Effect of cyclosporin A on rat kidney catecholamines. , 1990, Life sciences.

[170]  A. Michael,et al.  Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. , 1988, Kidney international.

[171]  G. Remuzzi,et al.  Adriamycin-induced glomerulosclerosis in the rat. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[172]  G. Remuzzi,et al.  Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[173]  W. Butler,et al.  AMPHOTERICIN B RENAL TOXICITY IN THE DOG. , 1964, The Journal of pharmacology and experimental therapeutics.